<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40391725</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Twenty Years of Disease-Modifying Anti-IBD Drug Use Preceding Colectomy for Refractory IBD-Associated Colitis.</ArticleTitle><Pagination><StartPage>978</StartPage><EndPage>983</EndPage><MedlinePgn>978-983</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003826</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Disease-modifying anti-IBD drugs such as infliximab have altered the treatment of IBD. Despite the increasing availability of disease-modifying anti-IBD drugs, many individuals with IBD still require surgical resection, and the role of disease-modifying anti-IBD drugs in delaying colectomy is limited.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess use patterns of disease-modifying anti-IBD drug use preceding colectomy for refractory IBD.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective analysis of institutional data.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Academic tertiary medical center from 2003 to 2022.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients with Crohn's disease or ulcerative colitis who underwent total abdominal colectomy or proctocolectomy for medically refractory disease were included.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Number and type of disease-modifying anti-IBD drugs used before colectomy and use of disease-modifying anti-IBD drugs over time.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 487 patients met inclusion criteria. Most patients had ulcerative colitis (77.8%) and were men (57.1%), with a mean age at diagnosis of 32.1 years. Two hundred eighty patients' first disease-modifying anti-IBD drug was an anti-tumor necrosis factor agent. We found no significant difference in time from diagnosis to colectomy when comparing those who initially received an anti-tumor necrosis factor versus a non-anti-tumor necrosis agent (8.29 vs 8.86 years, p = 0.39). Linear regression demonstrated that, with each decade, patients used about 1.5 additional disease-modifying anti-IBD drugs ( p &lt; 0.01) before surgery. The mean time between diagnosis and colectomy was 8.6 years. Accelerated failure time modeling demonstrated each additional disease-modifying anti-IBD drug was associated with a nonsignificant 5% increase in time between diagnosis and colectomy (1.05 [0.96-1.13], p = 0.25).</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Single-center, retrospective.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">During a 20-year period, patients with IBD-associated colitis who ultimately required colectomy received increasing numbers of disease-modifying anti-IBD drugs; however, each additional disease-modifying anti-IBD drug used did not significantly delay time to colectomy, nor did initial non-anti-tumor necrosis factor agent choice. These data suggest that a subset of patients are using increasing numbers of disease-modifying anti-IBD drugs that do not afford them meaningful time in delaying colectomy. See Video Abstract .</AbstractText><AbstractText Label="VEINTE AOS DE USO DE FRMACOS MODIFICADORES DE LA ENFERMEDAD INFLAMATORIA INTESTINAL TRAS UNA COLECTOMA POR COLITIS ASOCIADA A ENFERMEDAD INFLAMATORIA INTESTINAL REFRACTARIA" NlmCategory="UNASSIGNED">ANTECEDENTES:Los medicamentos modificadores de la enfermedad inflamatoria intestinal (DMAID, por sus siglas en ingl&#xe9;s), como el infliximab, han cambiado el tratamiento de la enfermedad inflamatoria intestinal. A pesar de la creciente disponibilidad de estos medicamentos, muchas personas con enfermedad inflamatoria intestinal siguen necesitando una resecci&#xf3;n quir&#xfa;rgica, y el papel de los medicamentos modificadores de la enfermedad inflamatoria intestinal para retrasar la colectom&#xed;a es limitado.OBJETIVO:Evaluar los patrones de uso de los medicamentos modificadores de la enfermedad inflamatoria intestinal antes de la colectom&#xed;a para la enfermedad inflamatoria intestinal refractaria.DISE&#xd1;O:An&#xe1;lisis retrospectivo de datos institucionales.ENTORNO:Centro m&#xe9;dico terciario acad&#xe9;mico entre 2003 y 2022.PACIENTES:Pacientes con enfermedad de Crohn o colitis ulcerosa que se sometieron a una colectom&#xed;a abdominal total o a una proctocolectom&#xed;a por enfermedad m&#xe9;dicamente refractaria.PRINCIPALES MEDIDAS DE RESULTADO:N&#xfa;mero y tipo de medicamentos modificadores de la enfermedad inflamatoria intestinal utilizados antes de la colectom&#xed;a y uso de medicamentos modificadores de la enfermedad inflamatoria intestinal a lo largo del tiempo.RESULTADOS:Un total de 487 pacientes cumplieron los criterios de inclusi&#xf3;n, la mayor&#xed;a de los cuales ten&#xed;an colitis ulcerosa (77,8 %) y eran hombres (57,1 %), con una edad media en el momento del diagn&#xf3;stico de 32,1 a&#xf1;os. El primer medicamento modificador de la enfermedad inflamatoria intestinal que recibieron 280 pacientes fue un agente anti-TNF. No se encontraron diferencias significativas en el tiempo transcurrido desde el diagn&#xf3;stico hasta la colectom&#xed;a al comparar a los que recibieron inicialmente un agente antitumoral necrosis factor frente a un agente no antitumoral necrosis (8,29 a&#xf1;os frente a 8,86 a&#xf1;os, p = 0,39). La regresi&#xf3;n lineal demostr&#xf3; que, con cada d&#xe9;cada, los pacientes utilizaban aproximadamente 1,5 medicamentos modificadores de la enfermedad inflamatoria intestinal adicionales ( p &lt; 0,01) antes de la cirug&#xed;a. El tiempo medio entre el diagn&#xf3;stico y la colectom&#xed;a fue de 8,6 a&#xf1;os. El modelo de tiempo de fracaso acelerado demostr&#xf3; que cada medicamento modificador de la enfermedad inflamatoria intestinal adicional se asociaba con un aumento no significativo del 5 % en el tiempo entre el diagn&#xf3;stico y la colectom&#xed;a (1,05 [0,96-1,13], p = 0,25).LIMITACIONES:Retrospectivo, de un solo centro.CONCLUSIONES:Durante un periodo de 20 a&#xf1;os, los pacientes con colitis asociada a enfermedad inflamatoria intestinal que finalmente requirieron colectom&#xed;a recibieron un n&#xfa;mero cada vez mayor de medicamentos modificadores de la enfermedad inflamatoria intestinal; sin embargo, cada medicamento modificador de la enfermedad inflamatoria intestinal adicional utilizado no retras&#xf3; significativamente el tiempo hasta la colectom&#xed;a, ni tampoco lo hizo la elecci&#xf3;n inicial de un agente no anti-TNF. Estos datos sugieren que un subgrupo de pacientes est&#xe1; utilizando un n&#xfa;mero cada vez mayor de medicamentos modificadores de la enfermedad inflamatoria intestinal que no les proporcionan un tiempo significativo para retrasar la colectom&#xed;a. (Traducci&#xf3;n-Dr. Aurian Garcia Gonzalez ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ziegler</LastName><ForeName>Olivia</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0003-2348-6683</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Penn State Hershey Medical Center, Hershey, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soderman</LastName><ForeName>Caroline J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Penn State College of Medicine, Hershey, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greene</LastName><ForeName>Alicia C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Surgery, Penn State Hershey Medical Center, Hershey, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deutsch</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Penn State Hershey Medical Center, Hershey, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scow</LastName><ForeName>Jeffrey S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Penn State Hershey Medical Center, Hershey, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coates</LastName><ForeName>Matthew D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, Penn State Hershey Medical Center, Hershey, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koltun</LastName><ForeName>Walter A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Penn State Hershey Medical Center, Hershey, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kulaylat</LastName><ForeName>Audrey S</ForeName><Initials>AS</Initials><Identifier Source="ORCID">0000-0001-6070-6791</Identifier><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Penn State Hershey Medical Center, Hershey, Pennsylvania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>B72HH48FLU</RegistryNumber><NameOfSubstance UI="D000069285">Infliximab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005765">Gastrointestinal Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003082" MajorTopicYN="Y">Colectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003093" MajorTopicYN="Y">Colitis, Ulcerative</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069285" MajorTopicYN="N">Infliximab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003424" MajorTopicYN="Y">Crohn Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005765" MajorTopicYN="Y">Gastrointestinal Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anti-IBD medications</Keyword><Keyword MajorTopicYN="N">Biologics</Keyword><Keyword MajorTopicYN="N">Crohn&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Disease-modifying anti-IBD drugs</Keyword><Keyword MajorTopicYN="N">IBD</Keyword><Keyword MajorTopicYN="N">Ulcerative colitis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>17</Day><Hour>18</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>20</Day><Hour>17</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>20</Day><Hour>7</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40391725</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003826</ArticleId><ArticleId IdType="pii">00003453-202508000-00011</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn&#x2019;s disease: medical treatment. J Crohns Colitis. 2020;14:4&#x2013;22.</Citation></Reference><Reference><Citation>Agrawal M, Jess T. Implications of the changing epidemiology of inflammatory bowel disease in a changing world. United Europ Gastroenterol J. 2022;10:1113&#x2013;1120.</Citation></Reference><Reference><Citation>Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S; AGA Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158:1450&#x2013;1461.</Citation></Reference><Reference><Citation>Sandborn WJ, Feagan BG, Rutgeerts P, et al.; GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn&#x2019;s disease. N Engl J Med. 2013;369:711&#x2013;721.</Citation></Reference><Reference><Citation>Feagan BG, Sandborn WJ, Gasink C, et al.; UNITI&#x2013;IM-UNITI Study Group. Ustekinumab as induction and maintenance therapy for Crohn&#x2019;s disease. N Engl J Med. 2016;375:1946&#x2013;1960.</Citation></Reference><Reference><Citation>Gros B, Kaplan GG. Ulcerative colitis in adults: a review. JAMA. 2023;330:951&#x2013;965.</Citation></Reference><Reference><Citation>Kobayashi T, Hibi T. Improving IBD outcomes in the era of many treatment options. Nat Rev Gastroenterol Hepatol. 2023;20:79&#x2013;80.</Citation></Reference><Reference><Citation>Devaraj B, Kaiser AM. Surgical management of ulcerative colitis in the era of biologicals. Inflamm Bowel Dis. 2015;21:208&#x2013;220.</Citation></Reference><Reference><Citation>Chapman TP, Satsangi J. Head-to-head biologic therapy in Crohn&#x2019;s disease. Lancet. 2022;399:2169&#x2013;2171.</Citation></Reference><Reference><Citation>Meserve J, Barsky M, Dulai PS. In the absence of head-to-head trials, what do real world studies tell us about the comparative effectiveness of biologics in Crohn&#x2019;s disease. Best Pract Res Clin Gastroenterol. 2019;38-39:101619.</Citation></Reference><Reference><Citation>Sands BE, Irving PM, Hoops T, et al.; SEAVUE Study Group. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn&#x2019;s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022;399:2200&#x2013;2211.</Citation></Reference><Reference><Citation>Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965&#x2013;990.</Citation></Reference><Reference><Citation>Khoudari G, Mansoor E, Click B, et al. Rates of intestinal resection and colectomy in inflammatory bowel disease patients after initiation of biologics: a cohort study. Clin Gastroenterol Hepatol. 2022;20:e974&#x2013;e983.</Citation></Reference><Reference><Citation>Bednarz W, Czopnik P, Wojtczak B, Olewi&#x144;ski R, Domos&#x142;awski P, Spodzieja J. Analysis of results of surgical treatment in Crohn&#x2019;s disease. Hepatogastroenterology. 2008;55:998&#x2013;1001.</Citation></Reference><Reference><Citation>Mankarious MM, Greene AC, Schaefer EW, et al. Is the writing on the wall? The relationship between the number of disease-modifying anti-inflammatory bowel disease drugs used and the risk of surgical resection. J Gastrointest Surg. 2024;28:836&#x2013;842.</Citation></Reference><Reference><Citation>Cohen BL, Fleshner P, Kane SV, et al. Prospective cohort study to investigate the safety of preoperative tumor necrosis factor inhibitor exposure in patients with inflammatory bowel disease undergoing intra-abdominal surgery. Gastroenterology. 2022;163:204&#x2013;221.</Citation></Reference><Reference><Citation>Billioud V, Ford AC, Tedesco ED, Colombel JF, Roblin X, Peyrin-Biroulet L. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. J Crohns Colitis. 2013;7:853&#x2013;867.</Citation></Reference><Reference><Citation>Zhu Z, Gao Z, Li K. Controversy of preoperative exposure to tumor necrosis factor inhibitors in surgical and infectious complications of inflammatory bowel disease. Gastroenterology. 2023;164:307&#x2013;308.</Citation></Reference><Reference><Citation>Stallmach A, Hagel S, Bruns T. Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol. 2010;24:167&#x2013;182.</Citation></Reference><Reference><Citation>Kopylov U, Vutcovici M, Kezouh A, Seidman E, Bitton A, Afif W. Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: a Quebec claims database study. Inflamm Bowel Dis. 2015;21:1847&#x2013;1853.</Citation></Reference><Reference><Citation>Mocci G, Marzo M, Papa A, Armuzzi A, Guidi L. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. J Crohns Colitis. 2013;7:769&#x2013;779.</Citation></Reference><Reference><Citation>Moroi R, Shiga H, Endo K, et al. Long-term prognosis of Japanese patients with Crohn&#x2019;s disease treated by switching anti-tumor necrosis factor-&#x3b1; antibodies. Inflamm Intest Dis. 2020;5:11&#x2013;19.</Citation></Reference><Reference><Citation>Berg DR, Colombel JF, Ungaro R. The role of early biologic therapy in inflammatory bowel disease. Inflamm Bowel Dis. 2019;25:1896&#x2013;1905.</Citation></Reference><Reference><Citation>Tsui JJ, Huynh HQ. Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn&#x2019;s disease? Ann Gastroenterol. 2018;31:413&#x2013;424.</Citation></Reference><Reference><Citation>Buisson A, Blanco L, Manlay L, et al. Top-down versus step-up strategies to prevent postoperative recurrence in Crohn&#x2019;s disease. Inflamm Bowel Dis. 2023;29:185&#x2013;194.</Citation></Reference><Reference><Citation>Shergill AK, Terdiman JP. Controversies in the treatment of Crohn&#x2019;s disease: the case for an accelerated step-up treatment approach. World J Gastroenterol. 2008;14:2670&#x2013;2677.</Citation></Reference><Reference><Citation>Danielsen AK. Life after stoma creation. Dan Med J. 2013;60:B4732.</Citation></Reference><Reference><Citation>Siegel CA. Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options. Gut. 2012;61:459&#x2013;465.</Citation></Reference><Reference><Citation>Stidham RW, Lee TCH, Higgins PDR, et al. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn&#x2019;s disease. Aliment Pharmacol Ther. 2014;39:1349&#x2013;1362.</Citation></Reference><Reference><Citation>Barr&#xe9; A, Colombel JF, Ungaro R. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease. Aliment Pharmacol Ther. 2018;47:896&#x2013;905.</Citation></Reference><Reference><Citation>Stevens TW, Matheeuwsen M, L&#xf6;nnkvist MH, et al. Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease&#x2014;personalised medicine in its infancy. Aliment Pharmacol Ther. 2018;48:1213&#x2013;1231.</Citation></Reference><Reference><Citation>Gisbert JP, Chaparro M. Predictors of primary response to biologic treatment [anti-TNF, vedolizumab, and ustekinumab] in patients with inflammatory bowel disease: from basic science to clinical practice. J Crohns Colitis. 2020;14:694&#x2013;709.</Citation></Reference><Reference><Citation>Bek S, Nielsen JV, Bojesen AB, et al. Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases. Aliment Pharmacol Ther. 2016;44:554&#x2013;567.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38502565</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Low Rates of Colorectal Cancer Screening in First-Degree Relatives of Our Patients: Are We Failing Them?</ArticleTitle><Pagination><StartPage>903</StartPage><EndPage>910</EndPage><MedlinePgn>903-910</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003189</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Guidelines recommend screening those with a family history of early-onset colorectal cancer at age 40 years or 10 years before the age of their relative's diagnosis. Currently, there is no literature reporting the screening rate in these individuals, and no protocols are in place to identify and target this population for screening awareness.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aimed to assess adherence to current screening guidelines among first-degree relatives of patients with early-onset colorectal cancer.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective and qualitative study involving a telephone survey where patients were asked about relative's screening status and barriers to screening.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Two community-based institutions between January 2018 and December 2021.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Individuals diagnosed with early-onset colorectal cancer who had undergone surgery at our institutions.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Rate of screening in first-degree relatives of our patients with early-onset colorectal cancer. Other factors measured included demographics, clinicopathologic characteristics, and screening barriers.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-six patients were identified. The survey response rate was 66.6% (n = 24). A total of 88 first-degree relatives who met the screening criteria resulted in 67.1% of patients (n = 59) having a known screening status. Of the 59 patients with known screening status, only 44% (n = 26) had undergone screening. Patients of Black race, having stage III/IV disease, having Medicare/Medicaid insurance, and living within Baltimore City County were more likely to have family members with unknown or no screening. Lack of insurance coverage was the most common barrier, which was noted in 12.5% of patients (n = 3), whereas 54.1% of patients (n = 13) reported no barriers to screening.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Retrospective design.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Most first-degree relatives of patients diagnosed with early-onset colorectal cancer do not undergo colorectal cancer screening. This could be attributed to the lack of protocols that could guarantee these individuals are informed of their elevated risk and the different options available for screening. Furthermore, our study suggests that racial and socioeconomic disparities exist among high-risk patients who should pursue screening. See Video Abstract .</AbstractText><AbstractText Label="BAJAS TASAS DE DETECCIN DEL CNCER COLORRECTAL EN LOS FAMILIARES DE PRIMER GRADO DE NUESTROS PACIENTES LES ESTAMOS FALLANDO" NlmCategory="UNASSIGNED">ANTECEDENTES:Las directrices recomiendan realizar pruebas de detecci&#xf3;n a las personas con antecedentes familiares de c&#xe1;ncer colorrectal de aparici&#xf3;n temprana a los 40 a&#xf1;os o 10 a&#xf1;os antes de la edad del diagn&#xf3;stico de su familiar. Actualmente, no hay literatura que informe la tasa de detecci&#xf3;n en estos individuos y no existen protocolos para identificar y dirigirse a esta poblaci&#xf3;n para concientizar sobre la detecci&#xf3;n.OBJETIVO:Evaluar el cumplimiento de las pautas de detecci&#xf3;n actuales entre los FDR de pacientes con c&#xe1;ncer colorrectal de aparici&#xf3;n temprana.DISE&#xd1;O:Estudio retrospectivo y cualitativo que incluy&#xf3; una encuesta telef&#xf3;nica en la que se pregunt&#xf3; a los pacientes sobre el estado de detecci&#xf3;n de sus familiares y las barreras para la detecci&#xf3;n.AJUSTES:Dos instituciones comunitarias entre enero de 2018 y diciembre de 2021.PACIENTES:Personas diagnosticadas con c&#xe1;ncer colorrectal de inicio temprano que hab&#xed;an sido intervenidas quir&#xfa;rgicamente en nuestras instituciones.PRINCIPALES MEDIDAS DE RESULTADO:Tasa de detecci&#xf3;n en familiares de primer grado de nuestros pacientes con c&#xe1;ncer colorrectal de aparici&#xf3;n temprana. Otros factores medidos incluyeron datos demogr&#xe1;ficos, caracter&#xed;sticas cl&#xed;nico-patol&#xf3;gicas y barreras de detecci&#xf3;n.RESULTADOS:Se identificaron treinta y seis pacientes. La tasa de respuesta a la encuesta fue del 66,6% (n = 24). Resultaron un total de 88 familiares de primer grado que cumplieron con los criterios para la detecci&#xf3;n, y el 67,1% (n = 59) ten&#xed;a un estado de detecci&#xf3;n conocido. De los 59 con estado de detecci&#xf3;n conocido, se inform&#xf3; que solo el 44% (n = 26) se hab&#xed;a sometido a pruebas de detecci&#xf3;n. Los pacientes de raza afroamericana, enfermedad en etapa III/IV, Medicare/Medicaid y que viv&#xed;an dentro del condado de la ciudad de Baltimore ten&#xed;an m&#xe1;s probabilidades de tener familiares con pruebas de detecci&#xf3;n desconocidas o sin ellas. La falta de cobertura de seguro fue la barrera m&#xe1;s com&#xfa;n observada por el 12,5% (n = 3); mientras que el 54,1% (n = 13) no inform&#xf3; ninguna barrera para el cribado.LIMITACIONES:Dise&#xf1;o retrospectivo.CONCLUSIONES:La mayor&#xed;a de los familiares de primer grado de pacientes diagnosticados con c&#xe1;ncer colorrectal de aparici&#xf3;n temprana no se someten a pruebas de detecci&#xf3;n de c&#xe1;ncer colorrectal. Esto podr&#xed;a atribuirse a la falta de protocolos que garanticen que estas personas est&#xe9;n informadas sobre su elevado riesgo y las diferentes opciones disponibles para el cribado. Adem&#xe1;s, nuestro estudio sugiere que existen disparidades raciales y socioecon&#xf3;micas entre los pacientes de alto riesgo que deber&#xed;an someterse a pruebas de detecci&#xf3;n. (Traducci&#xf3;n-Dr. Francisco M. Abarca-Rendon).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Almanzar</LastName><ForeName>Anyelin</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0003-5334-8270</Identifier><AffiliationInfo><Affiliation>Department of General Surgery, Medstar Franklin Square Medical Center, Rossville, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dahmani</LastName><ForeName>Sophia L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>School of Medicine, Georgetown University, Washington, District of Columbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoucair</LastName><ForeName>Sami</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Medstar Franklin Square Medical Center, Rossville, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alnajjar</LastName><ForeName>Said R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Medstar Franklin Square Medical Center, Rossville, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Kan Hong</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Medstar Franklin Square Medical Center, Rossville, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Vinay K</ForeName><Initials>VK</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Medstar Franklin Square Medical Center, Rossville, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lisle</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Medstar Franklin Square Medical Center, Rossville, Maryland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055088" MajorTopicYN="Y">Early Detection of Cancer</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019983" MajorTopicYN="N">Guideline Adherence</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008403" MajorTopicYN="N">Mass Screening</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036301" MajorTopicYN="N">Qualitative Research</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>13</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>19</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>19</Day><Hour>12</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38502565</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003189</ArticleId><ArticleId IdType="pii">00003453-202407000-00008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73:233&#x2013;254.</Citation></Reference><Reference><Citation>Venugopal A, Carethers JM. Epidemiology and biology of early onset colorectal cancer. EXCLI J. 2022;21:162&#x2013;182.</Citation></Reference><Reference><Citation>Lowery JT, Ahnen DJ, Schroy PC, et al. Understanding the contribution of family history to colorectal cancer risk and its clinical implications: a state-of-the-science review. Cancer. 2016;122:2633&#x2013;2645.</Citation></Reference><Reference><Citation>Schroy PC, Barrison AF, Ling BS, Wilson S, Geller AC. Family history and colorectal cancer screening: a survey of physician knowledge and practice patterns. Am J Gastroenterol. 2002;97:1031&#x2013;1036.</Citation></Reference><Reference><Citation>Center for Disease Control and Prevention. Family health history of colorectal (colon) cancer. https://www.cdc.gov/genomics/disease/colorectal_cancer/family_history_coloretal.htm . Published March 9, 2022. Accessed April 10, 2023.</Citation></Reference><Reference><Citation>Bronner K, Mesters I, Weiss-Meilnik A, et al. Do individuals with a family history of colorectal cancer adhere to medical recommendations for the prevention of colorectal cancer? Fam Cancer. 2013;12:629&#x2013;637.</Citation></Reference><Reference><Citation>Taylor DP, Cannon-Albright LA, Sweeney C, et al. Comparison of compliance for colorectal cancer screening and surveillance by colonoscopy based on risk. Genet Med. 2011;13:737&#x2013;743.</Citation></Reference><Reference><Citation>Lowery JT, Horick N, Kinney AY, et al. A randomized trial to increase colonoscopy screening in members of high-risk families in the colorectal cancer family registry and cancer genetics network. Cancer Epidemiol Biomarkers Prev. 2014;23:601&#x2013;610.</Citation></Reference><Reference><Citation>Bujanda L, Sarasqueta C, Zubiaurre L, et al.; EPICOLON Group. Low adherence to colonoscopy in the screening of first-degree relatives of patients with colorectal cancer. Gut. 2007;56:1714&#x2013;1718.</Citation></Reference><Reference><Citation>Courtney RJ, Paul CL, Carey ML, et al. A population-based cross-sectional study of colorectal cancer screening practices of first-degree relatives of colorectal cancer patients. BMC Cancer. 2013;13:13.</Citation></Reference><Reference><Citation>Tan KK, Lopez V, Wong ML, Koh GC. Uncovering the barriers to undergoing screening among first degree relatives of colorectal cancer patients: a review of qualitative literature. J Gastrointest Oncol. 2018;9:579&#x2013;588.</Citation></Reference><Reference><Citation>Sinicrope FA. Increasing incidence of early-onset colorectal cancer. N Engl J Med. 2022;386:1547&#x2013;1558.</Citation></Reference><Reference><Citation>Bailey CE, Hu C, You YN, et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg. 2015;150:17&#x2013;22.</Citation></Reference><Reference><Citation>Stoffel EM, Murphy CC. Epidemiology and mechanisms of the increasing incidence of colon and rectal cancers in young adults. Gastroenterology. 2020;158:341&#x2013;353.</Citation></Reference><Reference><Citation>Spaander MCW, Zauber AG, Syngal S, et al. Young-onset colorectal cancer. Nat Rev Dis Primers. 2023;9:21.</Citation></Reference><Reference><Citation>Muthukrishnan M, Arnold LD, James AS. Patients&#x2019; self-reported barriers to colon cancer screening in federally qualified health center settings. Prev Med Rep. 2019;15:100896.</Citation></Reference><Reference><Citation>Jackson CS, Oman M, Patel AM, Vega KJ. Health disparities in colorectal cancer among racial and ethnic minorities in the United States. J Gastrointest Oncol. 2016;7(suppl 1):S32&#x2013;S43.</Citation></Reference><Reference><Citation>Shah SK, Narcisse MR, Hallgren E, Felix HC, McElfish PA. Assessment of colorectal cancer screening disparities in us men and women using a demographically representative sample. Cancer Res Commun. 2022;2:561&#x2013;569.</Citation></Reference><Reference><Citation>Dougherty MK, Brenner AT, Crockett SD, et al. Evaluation of interventions intended to increase colorectal cancer screening rates in the United States: a systematic review and meta-analysis. JAMA Intern Med. 2018;178:1645&#x2013;1658.</Citation></Reference><Reference><Citation>Tai CH, Chen A, Khurana S, Mazurkiewicz R. Improving colorectal cancer screening compliance with resident education. Am J Gastroenterol. 2020;115:S1637&#x2013;S1638.</Citation></Reference><Reference><Citation>Parker S, Zipursky J, Ma H, Baumblatt GL, Siegel CA. A web-based multimedia program before colonoscopy increased knowledge and decreased anxiety, sedation requirement, and procedure time. J Clin Gastroenterol. 2018;52:519&#x2013;523.</Citation></Reference><Reference><Citation>Hart AR, Barone TL, Mayberry JF. Increasing compliance with colorectal cancer screening: the development of effective health education. Health Educ Res. 1997;12:171&#x2013;180.</Citation></Reference><Reference><Citation>Kew GS, Koh CJ. Strategies to improve persistent adherence in colorectal cancer screening. Gut Liver. 2020;14:546&#x2013;552.</Citation></Reference><Reference><Citation>Hassan C, Kaminski MF, Repici A. How to ensure patient adherence to colorectal cancer screening and surveillance in your practice. Gastroenterology. 2018;155:252&#x2013;257.</Citation></Reference><Reference><Citation>Uson PLS Jr, Riegert-Johnson D, Boardman L, et al. Germline cancer susceptibility gene testing in unselected patients with colorectal adenocarcinoma: a multicenter prospective study. Clin Gastroenterol Hepatol. 2022;20:e508&#x2013;e528.</Citation></Reference><Reference><Citation>Yurgelun MB, Kulke MH, Fuchs CS, et al. Cancer susceptibility gene mutations in individuals with colorectal cancer. J Clin Oncol. 2017;35:1086&#x2013;1095.</Citation></Reference><Reference><Citation>You YN, Moskowitz JB, Chang GJ, et al. Germline cancer risk profiles of patients with young-onset colorectal cancer: findings from a prospective universal germline testing and telegenetics program. Dis Colon Rectum. 2023;66:531&#x2013;542.</Citation></Reference><Reference><Citation>Pearlman R, Frankel WL, Swanson B, et al.; Ohio Colorectal Cancer Prevention Initiative Study Group. Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. JAMA Oncol. 2017;3:464&#x2013;471.</Citation></Reference><Reference><Citation>Pearlman R, Frankel WL, Swanson BJ, et al. Prospective statewide study of universal screening for hereditary colorectal cancer: the Ohio colorectal cancer prevention initiative. JCO Precis Oncol. 2021;5:779&#x2013;791.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31490829</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>10</Issue><PubDate><Year>2019</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Mental Health Symptoms in Patients With Familial Adenomatous Polyposis: An Observational Study.</ArticleTitle><Pagination><StartPage>1204</StartPage><EndPage>1211</EndPage><MedlinePgn>1204-1211</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000001459</ELocationID><Abstract><AbstractText Label="BACKGROUND">Almost all patients with familial adenomatous polyposis undergo abdominal surgery with a risk of disease and surgery-related complications. This, the familial nature of the syndrome, and its wide-ranging manifestations make patients prone to mental health symptoms. If this is true, patients need appropriate evaluation and treatment.</AbstractText><AbstractText Label="OBJECTIVE">The purpose of this study was to record the experience of mental health symptoms in a group of unselected patients with FAP.</AbstractText><AbstractText Label="DESIGN">We conducted an observational study using an anonymized mental health symptom survey for patients affected with familial adenomatous polyposis.</AbstractText><AbstractText Label="SETTINGS">The study was conducted using the Hereditary Colorectal Cancer Registry in a tertiary referral center.</AbstractText><AbstractText Label="PATIENTS">Patients affected with familial adenomatous polyposis were included.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Results of the mental health survey were measured.</AbstractText><AbstractText Label="RESULTS">Seventy nine of 100 patients completed the survey; 57 endorsed &#x2265;1 psychosocial symptom (72.2%). with a mean of 4 per patient. Nine patients (11.4%) met all 4 of the American Psychiatric Association diagnostic criteria for posttraumatic stress disorder, and 8 (10.1%) endorsed partial posttraumatic stress disorder criteria (3/4 symptoms). Patients who met all of the criteria for posttraumatic stress disorder had an average of 9.3 psychosocial symptoms each compared with 8.3 for those who met 3 of 4 and 2.2 for those who met &lt;3. Six patients endorsed suicidal thoughts, all of whom met 3 or 4 of the criteria for posttraumatic stress disorder.</AbstractText><AbstractText Label="LIMITATIONS">The study was limited by its referral bias toward severe cases and relatively small number of patients. Because of the limitations of an anonymous self-administered screening, no mental health diagnoses have been given.</AbstractText><AbstractText Label="CONCLUSIONS">Patients with familial adenomatous polyposis are at risk for mental health symptoms, which can be multiple and severe. Some patients need professional counseling. A correlation between familial adenomatous polyposis patients with posttraumatic stress disorder and suicidal ideation is important. See Video Abstract at http://links.lww.com/DCR/A995. S&#xcd;NTOMAS PSICOPATOL&#xd3;GICOS EN PACIENTES CON P&#xd3;LIPOSIS ADENOMATOSO FAMILIAR: UN ESTUDIO OBSERVACIONAL: Un mayor&#xed;a de pacientes con p&#xf3;liposis adenomatoso familiar (PAF) se someten a cirug&#xed;a abdominal con los riesgos de enfermedad propria y complicaciones relacionadas a cirug&#xed;a. Estos factores, la relaci&#xf3;n familiar del s&#xed;ndrome y sus manifestaciones altamente variables hacen que los pacientes sean propensos a psicopatolog&#xed;as. Si estas consideraciones son validas, los pacientes requieren evaluaci&#xf3;n y tratamiento adecuado.</AbstractText><AbstractText Label="OBJETIVO">Documentar la experiencia de los s&#xed;ntomas psicopatol&#xf3;gicos en un grupo de pacientes no seleccionados con PAF. DISE&#xd1;O:: Estudio observacional utilizando una encuesta an&#xf3;nima de s&#xed;ntomas psicopatol&#xf3;gicos en pacientes afectados con p&#xf3;liposis adenomatoso familiar.</AbstractText><AbstractText Label="AMBIENTE CLINICO">Registro de c&#xe1;ncer colorrectal hereditario en un centro de referencia de tercer nivel.</AbstractText><AbstractText Label="PACIENTES">Individuos afectados con p&#xf3;liposis adenomatoso familiar. OBJETIVOS PRINCIPALES A VALORACI&#xd3;N:: Resultados de la encuesta de salud mental.</AbstractText><AbstractText Label="RESULTADOS">Setenta y nueve de 100 pacientes completaron la encuesta; 57 afirmaron uno o m&#xe1;s s&#xed;ntomas psicosociales (72,2%) con un promedio de 4 por paciente. 9 (11,4%) pacientes cumplieron con los 4 criterios de diagn&#xf3;stico de la Asociaci&#xf3;n Estadounidense de Psiquiatr&#xed;a para el trastorno por estr&#xe9;s postraum&#xe1;tico, y 8 (10,1%) llenaron los criterios del trastorno de estr&#xe9;s postraum&#xe1;tico parcial (3/4 s&#xed;ntomas). Los pacientes que cumplieron con todos los criterios para el trastorno por estr&#xe9;s postraum&#xe1;tico tuvieron un promedio de 9.3 s&#xed;ntomas psicosociales cada uno, en comparaci&#xf3;n con 8.3 para los que cumplieron con 3/4 y 2.2 para los que cumplieron con &lt;3. 6 pacientes afirmaron pensamientos de suicidio, todos los cuales cumplieron con 3 o 4 de los criterios para el trastorno por estr&#xe9;s postraum&#xe1;tico.</AbstractText><AbstractText Label="LIMITACIONES">Sesgo de referencia hacia casos graves, y un n&#xfa;mero relativamente peque&#xf1;o de pacientes. Debido a las limitaciones de un examen an&#xf3;nimo auto administrado, no se confirmaron diagn&#xf3;sticos de psicopatolog&#xed;a.</AbstractText><AbstractText Label="CONCLUSIONES">Los pacientes con p&#xf3;liposis adenomatoso familiar tienen riesgo de s&#xed;ntomas de salud mental alterada que pueden ser m&#xfa;ltiples y graves. Algunos pacientes necesitan asesoramiento profesional. La correlaci&#xf3;n entre los pacientes con p&#xf3;liposis adenomatoso familiar con trastorno por estr&#xe9;s postraum&#xe1;tico y ideaci&#xf3;n suicida es importante. Vea el Resumen del Video en http://links.lww.com/DCR/A995.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Sanford R. Weiss M.D. Center for Hereditary Colorectal Neoplasia, Departments of Colorectal Surgery and Gastroenterology, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Church</LastName><ForeName>James</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>O'Malley</LastName><ForeName>Margaret</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>LaGuardia</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Heald</LastName><ForeName>Brandie</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Burke</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Kalady</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D011125" MajorTopicYN="N">Adenomatous Polyposis Coli</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008603" MajorTopicYN="Y">Mental Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31490829</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000001459</ArticleId><ArticleId IdType="pii">00003453-201910000-00010</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>